Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMER: Natalizumab for Ambulatory Measures in RRMS
NCT00871780Phase 4Completed
- Sponsor
- Biogen
- Start
- Aug 2009
- Primary completion
- Jul 2012
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoints: Timed 100-meter Walk Test at Week 48, Timed 25-foot Walk Test at Week 48 and 2 more. Started Aug 2009; status: completed.
02
Drugs
natalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00871780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00871780.